CRM Stock Overview
PZ Cormay S.A. develops, manufactures, and sells diagnostic reagents in Poland.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
PZ Cormay S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | zł0.59 |
52 Week High | zł0.84 |
52 Week Low | zł0.55 |
Beta | 0.71 |
1 Month Change | -8.13% |
3 Month Change | 3.16% |
1 Year Change | -26.50% |
3 Year Change | -57.70% |
5 Year Change | -51.64% |
Change since IPO | -65.41% |
Recent News & Updates
Shareholder Returns
CRM | PL Medical Equipment | PL Market | |
---|---|---|---|
7D | -2.0% | -0.08% | 2.1% |
1Y | -26.5% | 4.0% | 35.7% |
Return vs Industry: CRM underperformed the Polish Medical Equipment industry which returned 4% over the past year.
Return vs Market: CRM underperformed the Polish Market which returned 35.7% over the past year.
Price Volatility
CRM volatility | |
---|---|
CRM Average Weekly Movement | 4.5% |
Medical Equipment Industry Average Movement | 4.7% |
Market Average Movement | 5.0% |
10% most volatile stocks in PL Market | 9.6% |
10% least volatile stocks in PL Market | 3.3% |
Stable Share Price: CRM has not had significant price volatility in the past 3 months.
Volatility Over Time: CRM's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1985 | 222 | Flavio Finotello | https://cormay.com |
PZ Cormay S.A. develops, manufactures, and sells diagnostic reagents in Poland. It offers testing products for clinical chemistry, electrophoresis, hematology, veterinary, coagulology, blood group serology, immunology, immunochemistry, molecular biology, sampling, oncological surgery, and general analytics, as well as vacuum blood collection system. The company offers its products under the Orphée and Diesse brand names.
PZ Cormay S.A. Fundamentals Summary
CRM fundamental statistics | |
---|---|
Market cap | zł49.51m |
Earnings (TTM) | -zł5.08m |
Revenue (TTM) | zł84.06m |
0.6x
P/S Ratio-9.8x
P/E RatioIs CRM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CRM income statement (TTM) | |
---|---|
Revenue | zł84.06m |
Cost of Revenue | zł50.34m |
Gross Profit | zł33.72m |
Other Expenses | zł38.79m |
Earnings | -zł5.08m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Mar 29, 2024
Earnings per share (EPS) | -0.06 |
Gross Margin | 40.11% |
Net Profit Margin | -6.04% |
Debt/Equity Ratio | 0% |
How did CRM perform over the long term?
See historical performance and comparison